Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan & 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a high rate of tumor shrinkage allowing subsequent resection in patients with initial borderline resectable tumors and improved overall survival for all patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Per Pfeiffer
• Treatments: Irinotecan; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria: (major)

• non-metastatic pancreatic cancer

• Performance status 0-1

• Bilirubin < 1.5 UNL

• Written informed consent

Exclusion Criteria: (major)

• no prior abdominal radiotherapy

• no prior chemotherapy for pancratic cancer

• no severe comorbidity

• patients must be able to undergo potential abdominal surgery